Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 13, 2020 / 02:20PM GMT
Release Date Price: R$30.52 (-2.13%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Good morning. Welcome to the second day of BofA Virtual Vegas Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here at BofA. I have Alec Stranahan as well from my team. And we're really excited to have Lilly present. Speaking on behalf of Lilly, we have Patrik Jonsson, who is President of Lilly Bio-Medicines. Patrik, you there?

Patrik Jonsson
Eli Lilly and Company - Senior VP, Chief Customer Officer & President of Lilly USA

Yes, I am here. And good morning, Geoff.

Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

All right, perfect. Good morning. Yes, so the format for today is I'll ask Patrik a number of questions about mostly the I&I franchise as well as the neuro franchise. And then if interested, there is an ability to ask a question via the webcast on the Webex technology. So we can ask those to the extent that folks have them.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot